TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets is for patients with BRAF+ melanoma after surgery or patients with BRAF+ advanced melanoma.

**INDICATIONS**

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

- That has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and
- That has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.

TAFINLAR, in combination with MEKINIST, should not be used to treat people with a type of skin cancer called wild-type BRAF melanoma. MEKINIST should not be used to treat people who already have received a BRAF inhibitor for treatment of their melanoma and it did not work or is no longer working.

Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST, in combination, are right for you.

It is not known if TAFINLAR and MEKINIST, in combination, are safe and effective in children.

Please see Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TAFINLAR in combination with MEKINIST?

TAFINLAR and MEKINIST may cause serious side effects, including:

- Risk of new skin cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers.
- Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.

This brochure is meant to help you and those close to you understand your treatment as you begin your treatment journey with TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets combination therapy.

TAFINLAR + MEKINIST is used to treat 2 different stages of BRAF+ melanoma:

- Adjuvant (after surgery) treatment of BRAF+ melanoma to help prevent your melanoma from coming back after it has been removed by surgery
- Treatment of BRAF+ melanoma that is metastatic (has spread to other parts of the body: eg, the liver, lungs, or brain) or cannot be removed by surgery

TODAY YOU START THE JOURNEY

You are probably experiencing many emotions as you process all the information provided by your health care provider. The good news: you have a treatment option that’s made for your type of cancer, plus the support of your family, friends, and health care team.
UNDERSTANDING MELANOMA

Understanding your type of melanoma is the first part of your treatment journey. It will help you know why your health care provider has prescribed TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets for you and will help you in conversations with your health care team down the road.

What is melanoma?
Melanoma is a type of skin cancer that begins in melanocytes, the types of cells which give skin its color.

What is adjuvant treatment?
Melanoma can sometimes be removed by surgery. Health care providers will often recommend adjuvant treatment as well, which means you’re given additional treatment after surgery to further decrease the risk that the disease (in this case, melanoma) will come back.

What is unresectable melanoma?
If melanoma is inoperable, it’s considered unresectable; that is, the tumor(s) can’t be completely removed by surgery, either because they have spread to too many places or their location makes the surgery very challenging. Health care providers will prescribe other treatments to help slow the spread of the disease.

FROM DNA TO DIAGNOSIS: BRAF+ MELANOMA

There are some types of melanoma that are able to be treated with targeted therapy (treatments that identify and attack certain cancer cells). Targeted therapy can also affect healthy cells. One of those is your type of melanoma, BRAF+ (BRAF-positive) melanoma. Health care providers determined that your type of melanoma was BRAF+ by taking a sample of the tumor and analyzing its DNA.

If your melanoma is BRAF+, you have a change in your DNA, known as a mutation.
This means there is damage to a specific gene, the BRAF gene, causing cells to grow uncontrollably and leading to cancers such as melanoma. About 50% of patients with advanced melanoma have one of these mutations. BRAF V600E and V600K are 2 of the most common types of BRAF mutation.

Because you have one of these gene mutations, your health care provider prescribed you TAFINLAR + MEKINIST for your BRAF+ melanoma. Keep reading to find out how TAFINLAR + MEKINIST can help treat BRAF+ melanoma.

IMPORTANT SAFETY INFORMATION (continued)
Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.
Your health care provider should also check for cancers that may not occur on the skin. Tell your health care provider about any new symptoms that have developed while taking TAFINLAR and MEKINIST in combination.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
TAFINLAR + MEKINIST + MEKINIST for after surgery

TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets is a combination targeted therapy that can be used as adjuvant (after surgery) treatment of BRAF+ melanoma. Your health care provider has prescribed you TAFINLAR + MEKINIST to help prevent your melanoma from coming back after it has been removed by surgery.

How does TAFINLAR + MEKINIST work?

As a targeted combination therapy, TAFINLAR + MEKINIST helps inhibit out-of-control cell growth by blocking cell-growth signals associated with the BRAF gene. TAFINLAR and MEKINIST work together, with each targeting a different point in this cell-signaling pathway.

Medical research has shown that TAFINLAR + MEKINIST may help slow the growth of certain melanoma cancer cells with a BRAF mutation. TAFINLAR + MEKINIST has been studied in clinical trials of patients with BRAF+ melanoma (either V600E or V600K mutation-positive as determined by a US Food and Drug Administration [FDA]-approved test). Targeted therapy can also affect healthy cells.

TAFINLAR + MEKINIST can help prevent BRAF+ melanoma from coming back after it has been removed by surgery.

Benefits of TAFINLAR + MEKINIST therapy after surgery

The risk of cancer returning after surgery was reduced by more than 50%* More patients were cancer-free after treatment with TAFINLAR + MEKINIST*

53% RISK REDUCTION VS PLACEBO

62% CANCER-FREE AT FIRST CHECK-IN

43% CANCER-FREE AT FIRST CHECK-IN

* As demonstrated by a clinical trial that included 870 patients with BRAF V600E or V600K mutation-positive stage III melanoma that was previously removed by surgery. Patients were treated with a combination of TAFINLAR + MEKINIST or placebo for 12 months. The numbers listed above were taken from the first check-in, at which at least half of the patients had been monitored for 2.8 years.

IMPORTANT SAFETY INFORMATION (continued)

Inflammation of the intestines or tears (perforation) of the stomach or intestines.

MEKINIST, alone or in combination with TAFINLAR + MEKINIST, can cause inflammation of your intestines, or tears in the stomach or intestines that can lead to death.

Tell your health care provider immediately if you have any of the following symptoms:

• bleeding (see “Bleeding problems”)
• diarrhea (loose stools) or more bowel movements than usual
• stomach-area (abdomen) pain or tenderness
• fever
• nausea

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
TAFINLAR + MEKINIST + MEKINIST for advanced melanoma

TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets is a targeted therapy that can be used as treatment for BRAF+ metastatic or inoperable melanoma. Your health care provider has prescribed you TAFINLAR + MEKINIST to help slow the progression of your melanoma if you have tested positive for BRAF melanoma.

How does TAFINLAR + MEKINIST work?

As a targeted combination therapy, TAFINLAR + MEKINIST helps inhibit out-of-control cell growth by blocking cell-growth signals associated with the BRAF gene. TAFINLAR and MEKINIST work together, with each targeting a different point in this cell-signaling pathway. Medical research has shown that TAFINLAR + MEKINIST may help slow the growth of certain melanoma cancer cells with a BRAF mutation. TAFINLAR + MEKINIST has been studied in clinical trials of patients with BRAF+ melanoma (either V600E or V600K mutation-positive as determined by an FDA-approved test). Targeted therapy can also affect healthy cells.

TAFINLAR + MEKINIST can help slow the progression of BRAF+ melanoma

IMPORTANT SAFETY INFORMATION (continued)

Blood clots. TAFINLAR and MEKINIST in combination can cause blood clots in your arms or legs, which can travel to your lungs and lead to death. Get medical help right away if you have the following symptoms:

• chest pain
• sudden shortness of breath or trouble breathing
• pain in your legs with or without swelling
• swelling in your arms or legs
• a cool, pale arm or leg

As demonstrated by a clinical trial that included 423 adult patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma. Patients were treated with a combination of TAFINLAR + MEKINIST or TAFINLAR alone.

Benefits of TAFINLAR + MEKINIST therapy for advanced melanoma

Patients taking TAFINLAR + MEKINIST lived significantly longer than patients taking TAFINLAR*

About half of patients taking each treatment were alive after:

- TAFINLAR + MEKINIST
  - 25.1 months
- TAFINLAR
  - 18.7 months

Patients lived longer without their disease worsening with TAFINLAR + MEKINIST*

About half of patients taking each treatment were alive without their disease worsening after:

- TAFINLAR + MEKINIST
  - 9.3 months
- TAFINLAR
  - 8.8 months

More patients had their tumors shrink or disappear (known as the overall response rate) with TAFINLAR + MEKINIST than with TAFINLAR alone*

- TAFINLAR + MEKINIST
  - 66% overall response rate
- TAFINLAR
  - 51% overall response rate

*As demonstrated by a clinical trial that included 423 adult patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma. Patients were treated with a combination of TAFINLAR + MEKINIST or TAFINLAR alone.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
What are TAFINLAR and MEKINIST? TAFINLAR® (dabrafenib) capsules and MEKINIST® (trametinib) tablets are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

• That has spread to other parts of the body (metastatic) or cannot be removed by surgery (incurable), and
• That has a certain type of abnormal "BRAF" (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal "BRAF" gene from coming back after the cancer has been removed by surgery.

TAFINLAR, in combination with MEKINIST, should not be used to treat people with a type of skin cancer called wild-type BRAF melanoma. MEKINIST should not be used in combination with TAFINLAR and MEKINIST to treat people who already have received a BRAF inhibitor for treatment of their melanoma and it did not work or is no longer working.

Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST, in combination, are right for you.

It is not known if TAFINLAR and MEKINIST are safe and effective in children.

What is the most important information I should know about TAFINLAR in combination with MEKINIST? TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new skin cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk to your health care provider about your risk for these cancers.

Check your skin and tell your health care provider right away about any skin changes including a new wart, skin sore, or reddish bump that bleed or does not heal, or a mole that changes size or color.

Your health care provider should check your skin before treatment with TAFINLAR and MEKINIST, every 2 months during treatment and for up to 6 months after you stop taking TAFINLAR and MEKINIST to look for any new skin cancers. Your health care provider should also check for cancers that may not occur on the skin. Tell your health care provider about any new symptoms that develop during treatment with TAFINLAR and MEKINIST.

Bleeding problems. TAFINLAR and MEKINIST in combination can cause serious bleeding problems, especially in your brain or stomach, that can lead to death. Call your health care provider and get medical help right away if you have any signs of bleeding, including:

• headaches, dizziness, or feeling weak
• coughing up blood or blood clots
• vomiting blood or your vomit looks like “coffee grounds”
• red or black stools that look like tar

Inflammation of the intestines or tears (perforation) of the stomach or intestines. MEKINIST, alone or in combination with TAFINLAR, can cause severe intussusception or tears in the stomach or intestines that can lead to death. Tell your health care provider immediately if you have any of the following symptoms:

• coughing up blood or blood clots
• vomiting blood or your vomit looks like “coffee grounds”
• red or black stools that look like tar
• shortness of breath
• fever
• severe pain in your arms or legs
• or redness

Blood clots. TAFINLAR and MEKINIST in combination can cause blood clots in your arms or legs, which can travel to your lungs and lead to death. Get medical help right away if you have the following symptoms:

• chest pain
• sudden shortness of breath or trouble breathing
• pain in your legs with or without swelling
• swelling in your arms or legs
• a cool, pale arm or leg

Heart problems, including heart failure. Your health care provider should check your heart function before you start taking TAFINLAR and MEKINIST in combination, and during treatment. Call your health care provider right away if you have any of the following signs and symptoms of a heart problem:

• feeling like your heart is pounding or racing
• shortness of breath
• swelling of your ankles and feet
• feeling lightheaded

Eye problems. TAFINLAR and MEKINIST in combination, can cause severe eye problems that can lead to blindness. Call your health care provider right away if you get these symptoms of eye problems:

• blurred vision, loss of vision, or other vision changes
• seeing color dots
• halo (seeing blurred outline around objects)
• eye pain, swelling, or redness

Lung or breathing problems. TAFINLAR and MEKINIST, in combination, can cause lung or breathing problems.

Serious skin reactions. Rash and other skin reactions are common side effects of TAFINLAR and MEKINIST in combination. In some cases these rashes and other skin reactions can be severe or serious, and may need to be treated in a hospital. Call your health care provider if you get any of the following symptoms:

• skin rash that bothers you or does not go away
• acne
• redness, swelling, peeling, or tenderness of hands or feet
• skin redness

Increased blood sugar (hyperglycemia). Some people may develop high blood sugar or worsening diabetes during treatment with TAFINLAR and MEKINIST in combination. If you are diabetic, your health care provider should check your blood sugar levels daily during treatment with TAFINLAR and MEKINIST. Your diabetes medicine may need to be changed. Tell your health care provider if you have symptoms of severe high blood sugar such as increased thirst, urinating more often than normal, or urinating an increased amount of urine.
**SUMMARY OF IMPORTANT INFORMATION (continued)**

Glucose-6-phosphate dehydrogenase (G6PD) deficiency. TAFINLAR® (dabrafenib) capsules may cause healthy red blood cells to break down too easily in people with G6PD deficiency. This may lead to a type of anemia called hemolytic anemia, where the body does not have enough healthy red blood cells. Tell your health care provider if you have any of the signs or symptoms such as yellow skin (jaundice), weakness or dizziness, or shortness of breath.

What should I tell my health care provider before taking TAFINLAR and MEKINIST?

- Before you take TAFINLAR, in combination with MEKINIST® (trametinib) tablets, tell your health care provider about all of your medical conditions, including if you:
  - have had bleeding problems or blood clots
  - have stomach problems
  - have inflammation of the colon
  - have heart problems
  - have eye problems
  - have lung or breathing problems
  - have high blood pressure (hypertension)
  - have liver or kidney problems
  - have diabetes
  - are a man (including one who has had a vasectomy) with a female partner of reproductive potential
  - are menstruating women
  - are pregnant or plan to become pregnant
  - do not breastfeed

- TAFINLAR and MEKINIST, in combination, may harm your unborn baby. Women who are able to become pregnant should use effective birth control (contraception) during treatment with TAFINLAR and MEKINIST in combination, and for 4 months after stopping treatment with TAFINLAR and MEKINIST.

- Tell your health care provider if this is a concern for you during this time.

- If you are capable of having children, you should use another effective method of birth control while taking TAFINLAR and MEKINIST in combination. Talk to your health care provider about birth control methods that may be right for you during this time.

What other medications might interact with TAFINLAR and MEKINIST?

- The most common side effects of TAFINLAR and MEKINIST in combination are:
  - fever
  - fatigue
  - nausea
  - headache
  - rash
  - chills
  - diarrhea
  - vomiting
  - joint aches
  - muscle aches

General information about the safe and effective use of TAFINLAR and MEKINIST

Do not use TAFINLAR and MEKINIST for a condition for which it was not prescribed. Do not give TAFINLAR and MEKINIST to other people, even if they have the same symptoms that you have. It may harm them. You can ask your health care provider or pharmacist for information about TAFINLAR and MEKINIST that is written for health care professionals.

These are not all of the possible side effects of TAFINLAR and MEKINIST. For more information, talk with your health care provider or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
How to take TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets

Because it is a combination treatment of 2 different medications with different strengths, it’s very important to understand how to take TAFINLAR + MEKINIST the right way.

The recommended dosage of TAFINLAR + MEKINIST is 2 capsules of TAFINLAR (the dark pink capsule) twice a day (4 capsules each day) + 1 tablet of MEKINIST (the light pink circular tablet) once a day (1 tablet each day).

It’s also recommended that you take the TAFINLAR doses about 12 hours apart.

Since TAFINLAR + MEKINIST is an oral treatment, you’ll take it by mouth—at least 1 hour before or at least 2 hours after eating.

Do not open, crush, or break TAFINLAR capsules.

First Dose
Morning
TAFINLAR 150 mg (2 x 75 mg)

Second Dose
Evening
TAFINLAR 150 mg (2 x 75 mg)

AND

Once Daily
MEKINIST 2 mg (1 x 2 mg)

Take MEKINIST at the same time each day with either the morning dose or evening dose of TAFINLAR

Missed a dose of TAFINLAR + MEKINIST?

If you miss a dose of TAFINLAR and/or MEKINIST—don’t panic, it happens. Do take it as soon as you remember, unless:

• You’ve missed TAFINLAR and it is within 6 hours of your next scheduled dose, or
• You’ve missed MEKINIST and it is within 12 hours of your next scheduled dose

In either case, just take your next dose at the regular time. Do not make up for the missed dose.

It is important that you understand and follow your health care provider’s directions for taking TAFINLAR + MEKINIST. Do not change your dose or stop TAFINLAR or MEKINIST, unless your health care provider tells you to.

TIP: Develop a routine for taking your medicine that fits your daily schedule. For example, you can take TAFINLAR and MEKINIST in the morning, an hour before breakfast, and then take TAFINLAR again in the evening, 2 hours after dinner.

How to store TAFINLAR + MEKINIST

Storing TAFINLAR

• Store TAFINLAR at room temperature, between 68°F and 77°F

Storing MEKINIST

• Store MEKINIST in the refrigerator between 36°F and 46°F
• Keep MEKINIST dry and away from moisture and light
• The bottle of MEKINIST contains a packet that helps keep your medicine dry. Do not throw away this packet
• Keep MEKINIST in the original bottle. Do not place tablets in a pill box
• Safely throw away MEKINIST that is expired or no longer needed

IMPORTANT SAFETY INFORMATION (continued)

Heart problems, including heart failure. Your health care provider should check your heart function before you start taking TAFINLAR and MEKINIST in combination, and during treatment. Call your health care provider right away if you have any of the following signs and symptoms of a heart problem:

• feeling like your heart is pounding or racing
• shortness of breath
• swelling of your ankles and feet
• feeling lightheaded

Eye problems. TAFINLAR and MEKINIST, in combination, can cause severe eye problems that can lead to blindness. Call your health care provider right away if you get these symptoms of eye problems:

• blurred vision, loss of vision, or other vision changes
• seeing color dots
• halo (seeing blurred outline around objects)
• eye pain, swelling, or redness

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
1716

**IMPORTANT SAFETY INFORMATION (continued)**

Lung or breathing problems.

TAFINLAR and MEKINIST, in combination, can cause lung or breathing problems. Tell your health care provider if you have any new or worsening symptoms of lung or breathing problems, including:

- shortness of breath
- cough

**Fever: the most common side effect**

Fever is the most common side effect of treatment with TAFINLAR + MEKINIST combination therapy for 
BRAF+ melanoma—about half of patients will experience fever. Patients taking TAFINLAR + MEKINIST often experience fevers in the first month of treatment.

Think you may have a fever?

As soon as you start feeling unusually warm or cold, check your temperature. Call your health care provider right away if you get a fever while taking TAFINLAR + MEKINIST. He or she may recommend that you:

- Drink liquids (for example: water, soups, or ice pops)
- Get plenty of rest
- Place a cold cloth on your forehead if you feel hot
- Use over-the-counter antifever medicines

**Remember to listen to your body**

Keep track of your side effects, and inform your health care provider about any side effect that bothers you or that does not go away. When you begin TAFINLAR + MEKINIST, make sure to keep a list of all of your medicines, and show it to your health care provider whenever you get a new medicine; certain medicines may affect each other, resulting in side effects.

Watch videos with more tips for managing common side effects of TAFINLAR + MEKINIST at www.us.TafinlarMekinist.com

**Other common side effects**

The following side effects can also be experienced by those taking TAFINLAR + MEKINIST. Talk to your health care provider right away if you experience any side effects. Your health care provider may choose to modify, interrupt, or discontinue your dosage.

<table>
<thead>
<tr>
<th>If you’re experiencing:</th>
<th>Your health care provider might recommend:</th>
</tr>
</thead>
</table>
| Fatigue                 | • Exercise, which has been shown to help with cancer-related fatigue  
                          | • A regular routine of activity and rest, including eating, can also help |
| Headache                | • Over-the-counter pain relievers  
                          | • Lifestyle modifications including dietary changes, increased sleep, and stress reduction |
| Diarrhea                | • A specific diet plan  
                          | • Increase in fluids  
                          | • Decrease in greasy and/or spicy foods, and foods containing dairy  
                          | • In some cases diarrhea can be severe |
| Rash                    | • Limiting exposure to the sun  
                          | • Using a gentle, thick, alcohol-free emollient cream to soothe affected areas  
                          | • Note: in some cases, these rashes and other skin reactions can be severe and may need to be treated in a hospital |
| Joint Aches             | • Over-the-counter nonsteroidal anti-inflammatory drugs to help relieve pain and swelling  
                          | • Icing and resting the affected area |

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
SUPPORT DESIGNED FOR PATIENTS AND CAREGIVERS

• Insurance and Medicare education to help you understand the insurance process
• Financial assistance for eligible patients*
• Patient Navigators who provide 1-on-1 support specific to your Novartis medicine(s) (varies by product)
• Information about independent organizations that can assist with your day-to-day needs beyond medical care†
• Patient Support Counselors who are able to provide information in more than 160 languages
  *Novartis Pharmaceuticals Corporation does not guarantee success in obtaining reimbursement or financial assistance. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved.
  †All organizations are not-for-profit and/or government agencies, and are independent of Novartis Pharmaceuticals Corporation.

To learn more about what’s available, call 1-800-282-7630 or visit Patient.NovartisOncology.com.

Novartis Oncology Universal Co-pay Program

You may be eligible for immediate co-pay savings on your next prescription of TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets.

• Eligible patients with private insurance may pay $0 per month ($0 per month for a 30-day supply of TAFINLAR and $0 for a 30-day supply of MEKINIST). Co-pay of $0 is only for TAFINLAR and MEKINIST combination therapy.
• Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*

To find out if you are eligible for the Universal Co-pay Program, call 1-877-577-7756 or visit Copay.NovartisOncology.com.

Patient Assistance Now Oncology

Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.

To learn more, call 1-800-282-7630 or visit Patient.NovartisOncology.com.

Free Trial and Access Program

With the Free Trial and Access Program, you can receive a free supply of TAFINLAR and MEKINIST for a US Food and Drug Administration–approved indication. The supply can be shipped directly to your home or another convenient location so you can start treatment immediately. Program rules may vary by product.

Ask your health care professional to help you apply for the PANO Free Trial and Access Program.

Please see Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
Community and support are critical to helping you take on BRAF+ melanoma. The following organizations may be able to provide additional information, connections, and support for you and your loved ones during your TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) treatment journey. Several of the websites offer forums, where you can connect with other patients and caregivers.

Connecting with advocacy groups can help you build a community with others who understand what you’re experiencing.

AIM at Melanoma Foundation
www.aimatmelanoma.org
Melanoma Research Foundation
www.melanoma.org
Melanoma International Foundation
www.melanomainternational.org
Caregiver Action Network
www.caregiveraction.org
Cancer Support Community
www.cancersupportcommunity.org

The organizations and websites listed above are external to Novartis. Novartis does not have control over the information provided on these websites and, therefore, cannot guarantee their accuracy and completeness. Any information you receive from these sites should not replace the medical advice from your health care provider.

TAFINLAR + MEKINIST on Facebook
Like the TAFINLAR + MEKINIST page on Facebook to stay connected—find tips for treatment and managing side effects and hear stories from fellow patients and supporters.
www.facebook.com/TafinlarMekinist

IMPORTANT SAFETY INFORMATION (continued)
Fever. Fever is common during treatment with TAFINLAR and MEKINIST, but it may also be serious. When taking TAFINLAR and MEKINIST, in combination, fever may happen often or may be severe. In some cases, chills or shaking chills, too much fluid loss (dehydration), low blood pressure, dizziness, or kidney problems may happen with the fever. Call your health care provider right away if you get a fever while taking TAFINLAR or MEKINIST.

Supporters—take care of yourself, too
As a supporter of someone diagnosed with BRAF+ melanoma, your responsibilities may seem overwhelming at times. It is important to concentrate on the needs of your loved one without forgetting about your own. You can take steps to plan ahead and learn more about the disease, which can help you cope as you adjust to the changes in your life and the life of your loved one.

Remember, you are best suited to support your loved one in their fight against melanoma when you take care of yourself. Sometimes that just means taking a break, whether that means ordering takeout instead of cooking, or keeping up with your hobbies.

Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.
IMPORTANT SAFETY INFORMATION (continued)

Serious skin reactions. Rash and other skin reactions are common side effects of TAFINLAR® (dabrafenib) capsules and MEKINIST® (trametinib) tablets in combination. In some cases these rashes and other skin reactions can be severe or serious, and may need to be treated in a hospital. Call your health care provider if you get any of the following symptoms:
- skin rash that bothers you or does not go away
- acne
- redness, swelling, peeling, or tenderness of hands or feet
- skin redness

In increased blood sugar (hyperglycemia). Some people may develop high blood sugar or worsening diabetes during treatment with TAFINLAR and MEKINIST in combination. If you are diabetic, your health care provider should check your blood sugar levels closely during treatment with TAFINLAR and MEKINIST. Your diabetes medicine may need to be changed. Tell your health care provider if you have any of the following symptoms of severe high blood sugar:
- increased thirst
- urinating more often than normal, or urinating an increased amount of urine

TAFINLAR may cause healthy red blood cells to break down too early in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This may lead to a type of anemia called hemolytic anemia, where the body does not have enough healthy red blood cells. Tell your health care provider if you have any of the following signs or symptoms:
- yellow skin (jaundice)
- weakness or dizziness
- shortness of breath

TAFINLAR and MEKINIST, in combination, can harm your unborn baby. Women who are able to become pregnant should use effective birth control (contraception) during treatment with TAFINLAR and MEKINIST in combination, and for 4 months after stopping treatment with TAFINLAR and MEKINIST.

Birth control using hormones (such as birth control pills, injections, or transdermal systems) may not work as well while you are taking TAFINLAR and MEKINIST in combination. You should use another effective method of birth control while taking TAFINLAR and MEKINIST in combination.

Tell your health care provider about birth control methods that may be right for you during this time. Tell your health care provider right away if you become pregnant, or think you might be pregnant, during treatment with TAFINLAR and MEKINIST. Your diabetes medicine may need to be changed.

The most common side effects of TAFINLAR, in combination with MEKINIST, when used in patients with melanoma that has spread to other parts of the body or cannot be removed by surgery include:
- fever
- fatigue
- nausea
- headache
- rash
- chills
- diarrhea
- vomiting
- joint aches
- muscle aches

New or worsening high blood pressure (hypertension). Your health care provider should check your blood pressure during treatment with MEKINIST. Call your health care provider right away if you develop high blood pressure, your blood pressure worsens, or you have severe headache, lightheadedness, blurry vision, or dizziness.

Fertility problems. TAFINLAR and MEKINIST, in combination, may cause fertility problems in women. This could affect the ability to become pregnant. Talk to your health care provider if this is a concern for you. Low sperm counts. TAFINLAR may cause lower sperm counts in men. This could affect the ability to father a child. Talk to your health care provider if this is a concern for you.

Nursing mothers. It is not known if TAFINLAR and MEKINIST pass into breast milk. Do not breastfeed your baby during treatment with TAFINLAR and MEKINIST. Talk to your health care provider about the best way to feed your baby during this time.

These are not all of the possible side effects of TAFINLAR and MEKINIST. For more information about side effects, ask your health care provider or pharmacist.

Before you take TAFINLAR and MEKINIST in combination, tell your health care provider about all of your medical conditions, including if you:
- have had bleeding problems or blood clots
- have stomach problems
- have inflammation of the colon
- have heart problems
- have eye problems
- have lung or breathing problems
- have high blood pressure (hypertension)
- have liver or kidney problems
- have diabetes
- are a man (including one who has had a vasectomy) with a female partner of reproductive potential
- men (including those who have had a vasectomy) should use condoms during sexual intercourse during treatment with TAFINLAR and MEKINIST and for at least 4 months after your last dose of TAFINLAR and MEKINIST
- plan to have surgery, dental, or other medical procedures
- have a deficiency of the G6PD enzyme
- are pregnant or plan to become pregnant
- are breastfeeding or plan to breastfeed
TAFINLAR® (dabrafenib) capsules + MEKINIST®
(trametinib) tablets is for patients with BRAF+
melanoma after surgery or patients with BRAF+
advanced melanoma

IMPORTANT SAFETY INFORMATION (continued)
Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.
Please read the Medication Guide for TAFINLAR and the Patient Information for MEKINIST, and discuss any questions you have with your health care provider.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see additional Important Safety Information throughout this brochure, and the Summary of Important Information on pages 10 to 13.